News
Press Release | May 22, 2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
Press Release | May 19, 2023
Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
Press Release | May 19, 2023
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
News | May 16, 2023
Cyrus Bio Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article
Press Release | April 27, 2023
Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Press Release | April 26, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines
Press Release | April 18, 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
Press Release | April 13, 2023
Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline
News | March 22, 2023
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Press Release | March 16, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
News | March 15, 2023
Passage of FDA Modernization Act 2.0 Opens Opportunities for New Alternative Methods in Drug Development
Press Release | March 13, 2023
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Press Release | March 9, 2023
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies
Press Release | March 6, 2023
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
Press Release | March 3, 2023
Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS
Press Release | March 2, 2023
Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company
Press Release | March 1, 2023
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
1
2